{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:39:54Z","timestamp":1793194794384,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.lungcan.2025.108702","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:31:23Z","timestamp":1754433083000},"page":"108702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study"],"prefix":"10.1016","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1543-9281","authenticated-orcid":false,"given":"Rajiv","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Buchmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-8888","authenticated-orcid":false,"given":"Hans-Georg","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-6427","authenticated-orcid":false,"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hoffknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kuon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7538","authenticated-orcid":false,"given":"Martin","family":"Faehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-7924","authenticated-orcid":false,"given":"Julia","family":"Roeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7045-795X","authenticated-orcid":false,"given":"Paolo","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Olchers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura V.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-055X","authenticated-orcid":false,"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9483","key":"10.1016\/j.lungcan.2025.108702_b0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108702_b0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2025.108702_b0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108702_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","author":"Peters","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","author":"Kindler","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108702_b0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10419","key":"10.1016\/j.lungcan.2025.108702_b0035","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108702_b0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108702_b0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108702_b0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108702_b0055","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108702_b0060","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108702_b0065","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108702_b0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0075","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108702_b0080","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.15213","article-title":"PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach","volume":"24","author":"Barbarino","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.lungcan.2025.108702_b0085","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-22-0635","article-title":"BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification","author":"Barnett","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108702_b0090","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108702_b0095","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108702_b0100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108702_b0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0681","article-title":"A novel irreversible TEAD inhibitor, SWTX-143, blocks hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models","volume":"23","author":"Hillen","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108702_b0110","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108702_b0115","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108702_b0120","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0125","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | Protocol Development | CTEP https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50 (accessed 17th Jan 2025)."},{"key":"10.1016\/j.lungcan.2025.108702_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108702_b0135","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-world efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: the meso-immune (GFPC 04-2021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108702_b0145","doi-asserted-by":"crossref","unstructured":"D. Enrico, J.E. Gomez, D. Aguirre, et al., Efficacy of first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma: a multicenter real-world study (immunomeso LATAM). Clin. Lung Cancer, 25(8) (2024) 723-731 e2, doi:10.1016\/j.cllc.2024.09.005.","DOI":"10.1016\/j.cllc.2024.09.005"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108702_b0150","article-title":"Real-world outcomes of patients with malignant pleural mesothelioma receiving a combination of ipilimumab and nivolumab as first- or later-line treatment","volume":"5","author":"Schmid","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108702_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104123","article-title":"Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA","volume":"10","author":"Douma","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108702_b0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2025.108702_b0165","doi-asserted-by":"crossref","first-page":"8556","DOI":"10.1200\/JCO.2021.39.15_suppl.8556","article-title":"Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy","volume":"39","author":"Offin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","volume":"11","author":"Daniello","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108702_b0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2022.05.018","article-title":"A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial","volume":"169","author":"Banna","year":"2022","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500594X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022500594X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:40:49Z","timestamp":1757083249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022500594X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"alternative-id":["S016950022500594X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108702","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108702"}}